ArticleThe clinical respiratory journal2025
Evaluation of Predisposing Factors and Coexisting Diseases in the Development of Chronic Thromboembolic Pulmonary Disease.
Article in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Predisposing Factors and Coexisting Diseases in the Development of Chronic Thromboembolic Pulmonary Disease.The clinical respiratory journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe objective of this study was to examine the development of chronic thromboembolic pulmonary disease (CTEPD) incidence, risk factors, and coexisting medical conditions following an episode of acute pulmonary embolism (PE). MATERIALS: This retrospective, cross-sectional study analyzed data from 722 patients diagnosed with PE. Group I (n = 663), consisting of individuals who did not develop CTEPD, and Group II (n = 59), comprising those who progressed to CTEPD. CTEPD were divided into two subgroups as chronic thromboembolic pulmonary hypertension (CTEPH, n = 23) and without pulmonary hypertension (PH) (n = 36). The groups were compared based on demographic features, comorbid conditions, risk factors, and initial systolic pulmonary artery pressure (sPAP) values.
resultsCTEPD was observed in 59 patients (8.2%). Chronic obstructive pulmonary disease, coronary artery disease, and elevated baseline sPAP demonstrated a significant association with CTEPD (p = 0.003, p = 0.041, and p = 0.024, respectively). Immobilization was found to be significantly more prevalent in Group I (p = 0.032). In the multivariate logistic regression analysis, each 1 mmHg increase in baseline sPAP was associated with a 1.04-fold elevation in the risk of CTEPD development (95% confidence interval [CI]: 1.02-1.05; p < 0.001). Additionally, a 1-year decrease in age was linked to a 1.03-fold increase in the probability of developing CTEPD (95% CI: 1.01-1.05; p = 0.003). No significant differences were found between patients with CTEPH and those with CTEPD without PH.
conclusionThese findings highlight the important role of comorbid conditions in the development of CTEPD. It is important to optimize the clinical management of patients with such comorbidities to reduce the risk of CTEPD development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.